Résumé
Atypical features were incorporated into the American Psychiatric Association's Diagnostic and Statistical Manual, Fourth Edition (DSM-IV, 1994) as an illness specifier for major depression and dysthymia. The validity of depression with atypical features was supported by differences relative to depression with melancholic features in syndromal symptoms, course of illness, biology, family history, and treatment response. This paper reviews post-DSM-IV literature relevant to the validity of depression with atypical features. Most studies support the pre-DSM-IV findings. Again, course of illness, biological, family, and treatment differences are shown between melancholia and depression with atypical features. Several biologic studies report nondepressed controls have mean values between depressed subjects having atypical features and other depressed patients. This suggests atypical depression is a distinct depressive group rather than a milder form of melancholia. In addition, some studies show distinctions between depressed subjects with atypical features and those having neither atypical nor melancholic features. As depression with atypical features separates not only from melancholia but also from other depressed groups and controls over a range of meaningful distinctions, we conclude it is a valid clinical syndrome, useful both heuristically and in driving treatment decisions.
Langue d'origine | English |
---|---|
Pages (de-à) | 2625-2632 |
Nombre de pages | 8 |
Journal | Neuropsychopharmacology |
Volume | 34 |
Numéro de publication | 13 |
DOI | |
Statut de publication | Published - déc. 2009 |
Financement
During the past 3 years, Dr Stewart has received honoraria from Bristol-Myers-Squibb and Pfizer, consulted with Biovail and Merck, and received study support from Eli Lilly. Dr Stewart received no remuneration connected with the writing of this paper or for the work upon which the paper is based. Dr Klein has nothing to disclose. During the past 5 years, Dr McGrath has received research support from the NIMH, NIAAA, NY State Department of Mental Hygiene, NARSAD, Research Foundation for Mental Hygiene (NY), GSK, Eli Lilly, and Organon, Lipha Pharmaceuticals. He has consulted for GSK, Somerset Pharmaceuticals, Novartis, Sanofi-Aventis, and Roche.
Bailleurs de fonds | Numéro du bailleur de fonds |
---|---|
NY State Department of Mental Hygiene | |
RESEARCH FOUNDATION FOR MENTAL HYGIENE | |
National Institute of Mental Health | |
National Institute on Alcohol Abuse and Alcoholism | |
Eli Lilly and Company | |
National Alliance for Research on Schizophrenia and Depression | |
GlaxoSmithKline Australia |
ASJC Scopus Subject Areas
- Pharmacology
- Psychiatry and Mental health